<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39349557</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Modeling the burden of long COVID in California with quality adjusted life-years (QALYS).</ArticleTitle><Pagination><StartPage>22663</StartPage><MedlinePgn>22663</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22663</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-73160-x</ELocationID><Abstract><AbstractText>Individuals infected with SARS-CoV-2 may develop post-acute sequelae of COVID-19 ("long COVID") even after asymptomatic or mild acute illness. Including time varying COVID symptom severity can provide more informative burden estimates for public health response. Using a compartmental model driven by confirmed cases, this study estimated long COVID burden by age group (0-4, 5-17, 18-49, 50-64, 65+) in California as measured by the cumulative and severity-specific proportion of quality-adjusted life years (QALYs) lost. Long COVID symptoms were grouped into severe, moderate, and mild categories based on estimates from the Global Burden of Disease study, and symptoms were assumed to decrease in severity in the model before full recovery. All 10,945,079 confirmed COVID-19 cases reported to the California Department of Public Health between March 1, 2020, and December 31, 2022, were included in the analysis. Most estimated long COVID-specific QALYs [59,514 (range: 10,372-180,257)] lost in California were concentrated in adults 18-49 (31,592; 53.1%). Relative to other age groups, older adults (65+) lost proportionally more QALYs from severe long COVID (1,366/6,984; 20%). Due to changing case ascertainment over time, this analysis might underestimate the actual total burden. In global sensitivity analysis, estimates of QALYs lost were most sensitive to the proportion of individuals that developed long COVID and proportion of cases with each initial level of long COVID symptom severity (mild/moderate/severe). Models like this analysis can help translate observable metrics such as cases and hospitalizations into quantitative estimates of long COVID burden that are currently difficult to directly measure. Unlike the observed relationship between age and incident severe outcomes for COVID-19, this study points to the potential cumulative impact of mild long COVID symptoms in younger individuals.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8694-4058</Identifier><AffiliationInfo><Affiliation>Division of Communicable Disease Control, California Department of Public Health, Richmond, USA. Sophie.Zhu@cdph.ca.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Microbiology, and Immunology, University of California, Davis, USA. Sophie.Zhu@cdph.ca.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Kalyani</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Communicable Disease Control, California Department of Public Health, Richmond, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pry</LastName><ForeName>Jake M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Communicable Disease Control, California Department of Public Health, Richmond, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Seema</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Communicable Disease Control, California Department of Public Health, Richmond, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Lauren A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0003-3852-5374</Identifier><AffiliationInfo><Affiliation>Division of Communicable Disease Control, California Department of Public Health, Richmond, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le&#xf3;n</LastName><ForeName>Tom&#xe1;s M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-7633-677X</Identifier><AffiliationInfo><Affiliation>Division of Communicable Disease Control, California Department of Public Health, Richmond, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 CK000539</GrantID><Acronym>CK</Acronym><Agency>NCEZID CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002140" MajorTopicYN="N" Type="Geographic">California</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="Y">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349557</ArticleId><ArticleId IdType="pmc">PMC11443048</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-73160-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-73160-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC. Post-COVID Conditions. Centers for Disease Control and Prevention. Published September 1, 2022. Accessed December 12, 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>Coronavirus disease (COVID-19): Post COVID-19 condition. Accessed December 12, 2022. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition</Citation></Reference><Reference><Citation>Tenforde, M. W. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69. 10.15585/mmwr.mm6930e1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le, J. et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): A prospective cohort study. Clin. Infect. Dis.74(7), 1191&#x2013;1198. 10.1093/cid/ciab611 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong, S. J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis.53(10), 737&#x2013;754. 10.1080/23744235.2021.1924397 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C., Haupert, S. R., Zimmermann, L., Shi, X., Fritsche, L. G. &amp; Mukherjee, B. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review. J. Infect. Dis. Published online April 16, 2022:jiac136. 10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., Assaf, G. S., McCorkell, L., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 38. 10.1016/j.eclinm.2021.101019 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto, L. &amp; Sacrist&#xe1;n, J. A. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes1, 80. 10.1186/1477-7525-1-80 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317370</ArticleId><ArticleId IdType="pubmed">14687421</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA328(16), 1604&#x2013;1615. 10.1001/jama.2022.18931 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Adjei, S. et al. Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods&#x2014;United States, April 2020-June 2022. MMWR Morb. Mortal. Wkly. Rep.71(37), 1182&#x2013;1189. 10.15585/mmwr.mm7137a4 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484808</ArticleId><ArticleId IdType="pubmed">36107788</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, C., Luteijn, M., Letton, W., Robertson, J. &amp; McDonald, S. A model framework for projecting the prevalence and impact of Long-COVID in the UK. PLOS ONE16(12), e0260843. 10.1371/journal.pone.0260843 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639065</ArticleId><ArticleId IdType="pubmed">34855874</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan, R. et al. A review of mathematical model-based scenario analysis and interventions for COVID-19. Comput. Methods Programs Biomed.209, 106301. 10.1016/j.cmpb.2021.106301 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314871</ArticleId><ArticleId IdType="pubmed">34392001</ArticleId></ArticleIdList></Reference><Reference><Citation>Azar, K. M. J. et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff. (Millwood).39(7), 1253&#x2013;1262. 10.1377/hlthaff.2020.00598 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32437224</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitsma, M. B. et al. Racial/ethnic disparities in COVID-19 exposure risk, testing, and cases at the subcounty level in California. Health Aff. (Millwood).40(6), 870&#x2013;878. 10.1377/hlthaff.2021.00098 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458028</ArticleId><ArticleId IdType="pubmed">33979192</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Y. et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler looking for clarity in the haze of the pandemic. Clin. Nurs. Res.31(8), 1390&#x2013;1398. 10.1177/10547738221125632 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510954</ArticleId><ArticleId IdType="pubmed">36154716</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomogida, K. et al. Post-acute sequelae of SARS-CoV-2 infection among adults aged &#x2265;18 Years&#x2014;Long Beach, California, April 1&#x2013;December 10, 2020. Morb. Mortal. Wkly. Rep.70(37), 1274&#x2013;1277. 10.15585/mmwr.mm7037a2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Laughlin, K. N. et al. Study protocol for the innovative support for patients with SARS-COV-2 infections registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLOS ONE17(3), e0264260. 10.1371/journal.pone.0264260 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893622</ArticleId><ArticleId IdType="pubmed">35239680</ArticleId></ArticleIdList></Reference><Reference><Citation>California Department of Public Health. CalScope. Accessed March 1, 2023. https://www.cdph.ca.gov/Programs/OPA/Pages/Communications-Toolkits/Calscope.aspx</Citation></Reference><Reference><Citation>Menni, C. et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet399(10335), 1618&#x2013;1624. 10.1016/S0140-6736(22)00327-0 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin, M. et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg. Health Eur.6, 100122. 10.1016/j.lanepe.2021.100122 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova, A., Kudryavtsev, I., Starshinova, A, et al. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 10(11). 10.3390/pathogens10111408 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>California Department of Finance. California 2020 Population by Age. Accessed November 16, 2023. https://dof.ca.gov/forecasting/demographics/</Citation></Reference><Reference><Citation>California Department of Public Health. COVID-19 cases dashboard v2.0. Tableau Software. Accessed March 28, 2023. https://public.tableau.com/views/COVID-19CasesDashboardv2_0/CaseStatistics?</Citation></Reference><Reference><Citation>Perlis, R. H. et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw. Open5(10), e2238804. 10.1001/jamanetworkopen.2022.38804 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel, M. A. et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J. Am. Med. Inform. Assoc.28(3), 427&#x2013;443. 10.1093/jamia/ocaa196 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, J., Dhingra, R., Gambhir, M. &amp; Remais, J. V. Sensitivity analysis of infectious disease models: methods, advances and their application. J. R. Soc. Interface10(86), 20121018. 10.1098/rsif.2012.1018 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730677</ArticleId><ArticleId IdType="pubmed">23864497</ArticleId></ArticleIdList></Reference><Reference><Citation>Blower, S. M. &amp; Dowlatabadi, H. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int. Stat. Rev. Rev. Int. Stat.62(2), 229&#x2013;243. 10.2307/1403510 (1994).</Citation></Reference><Reference><Citation>Marino, S., Hogue, I. B., Ray, C. J. &amp; Kirschner, D. E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol.254(1), 178&#x2013;196. 10.1016/j.jtbi.2008.04.011 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570191</ArticleId><ArticleId IdType="pubmed">18572196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckay, M. D., Beckman, R. J. &amp; Conover, W. J. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics42(1), 55&#x2013;61. 10.1080/00401706.2000.10485979 (2000).</Citation></Reference><Reference><Citation>Carnell, R. lhs: Latin Hypercube Samples. Published online March 22, 2022. Accessed December 12, 2022. https://CRAN.R-project.org/package=lhs</Citation></Reference><Reference><Citation>Bartsch, S. M. et al. The potential health care costs and resource use associated with COVID-19 in the United States. Health Aff. (Millwood)39(6), 927&#x2013;935. 10.1377/hlthaff.2020.00426 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11027994</ArticleId><ArticleId IdType="pubmed">32324428</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco, M. et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J. Med. Econ.24(1), 308&#x2013;317. 10.1080/13696998.2021.1886109 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33555956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi, B. et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: Nationwide cohort study. BMJ380, e072529. 10.1136/bmj-2022-072529 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach, K. New data shows long Covid is keeping as many as 4 million people out of work. Brookings. Published August 24, 2022. Accessed January 23, 2023. https://www.brookings.edu/research/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/</Citation></Reference><Reference><Citation>Tsuzuki, S. &amp; Beutels, P. The estimated disease burden of COVID-19 in Japan from 2020 to 2021. Published online December 15, 2022:2022.12.14.22283492. 10.1101/2022.12.14.22283492</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10210821</ArticleId><ArticleId IdType="pubmed">37290316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri, S., Calleja, N., Devleesschauwer, B. &amp; Wyper, G. M. A. Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full year. BMC Public Health21(1), 1827. 10.1186/s12889-021-11893-4 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8501913</ArticleId><ArticleId IdType="pubmed">34627228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyper, G. M. A. et al. Measuring disability-adjusted life years (DALYs) due to COVID-19 in Scotland, 2020. Arch. Public Health80(1), 105. 10.1186/s13690-022-00862-x (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8972687</ArticleId><ArticleId IdType="pubmed">35365228</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as, C. et al. Post&#x2013;COVID-19 symptoms 2 years after SARS-CoV-2 infection among hospitalized vs nonhospitalized patients. JAMA Netw. Open5(11), e2242106. 10.1001/jamanetworkopen.2022.42106 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667330</ArticleId><ArticleId IdType="pubmed">36378309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, D. et al. Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. BMJ377, e069676. 10.1136/bmj-2021-069676 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlile, O. et al. Impact of long COVID on health-related quality-of-life: An OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT). Lancet Region. Health-Europe1, 40 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11059448</ArticleId><ArticleId IdType="pubmed">38689605</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafferty, E., Unsal, A., Kirwin, E., of Alberta U, of Manchester U, Kingdom U. Influenza and Other Respiratory Infections: Healthcare costs and effects of post-COVID-19 condition in Canada. Canada Communicable Disease Report.49(10), 425 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10936747</ArticleId><ArticleId IdType="pubmed">38481650</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo, S. M. et al. Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J. Gen. Intern. Med.37(8), 1988&#x2013;1995 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff, E. R. et al. Coding long COVID: Characterizing a new disease through an ICD-10 lens. BMC Med.21(1), 58. 10.1186/s12916-023-02737-6 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Long COVID&#x2014;Household Pulse Survey &#x2013; COVID-19. Published February 21, 2023. Accessed March 1, 2023. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm</Citation></Reference><Reference><Citation>Tanne, J. H. Covid-19: US studies show racial and ethnic disparities in long covid. BMJ.380, p535. 10.1136/bmj.p535 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36878599</ArticleId></ArticleIdList></Reference><Reference><Citation>Khullar, D., Zhang, Y., Zang, C., et al. Racial/ethnic disparities in post-acute sequelae of SARS-CoV-2 Infection in New York: an &#xa9;-Based Cohort Study from the RECOVER Program. J Gen Intern Med. Published online February 16, 2023. 10.1007/s11606-022-07997-1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933823</ArticleId><ArticleId IdType="pubmed">36795327</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman, E., Puspitarani, G. A., Enright, J. &amp; Kao, R. R. Ascertainment rate of SARS-CoV-2 infections from healthcare and community testing in the UK. J. Theor. Biol.558, 111333. 10.1016/j.jtbi.2022.111333 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9636607</ArticleId><ArticleId IdType="pubmed">36347306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrotra, M. L., Lim, E., Lamba, K., Kamali, A., Lai, K. W., Meza, E., Szeto, I., Robinson, P., Tsai, C. T., Gebhart, D. &amp; Fonseca, N. CalScope: monitoring severe acute respiratory syndrome coronavirus 2 seroprevalence from vaccination and prior infection in adults and children in California May 2021&#x2013;July 2021. InOpen Forum Infectious Diseases 2022 Jul 1 (Vol. 9, No. 7, p. ofac246). Oxford University Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129171</ArticleId><ArticleId IdType="pubmed">35855959</ArticleId></ArticleIdList></Reference><Reference><Citation>California Department of Public Health. Assessing the impact of COVID-19 in California. Published March 9, 2022. Accessed July 9, 2024. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Assessing-Impact-COVID-19-California.aspx</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>